200 related articles for article (PubMed ID: 30643575)
1. Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.
Bertaglia V; Vallone S; Pacchiana MV; Novello S
Lung Cancer Manag; 2017 Dec; 6(3):93-107. PubMed ID: 30643575
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Features of Advanced Squamous NSCLC.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn P; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Stinchcombe TE; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Sep; 11(9):1411-22. PubMed ID: 27296106
[TBL] [Abstract][Full Text] [Related]
3. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Wakelee H; Thatcher N
J Thorac Oncol; 2018 Feb; 13(2):165-183. PubMed ID: 29175116
[TBL] [Abstract][Full Text] [Related]
4. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Langer CJ; Obasaju C; Bunn P; Bonomi P; Gandara D; Hirsch FR; Kim ES; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Socinski MA; Spigel DR; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Dec; 11(12):2066-2081. PubMed ID: 27575423
[TBL] [Abstract][Full Text] [Related]
5. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
[TBL] [Abstract][Full Text] [Related]
6. Mouse models in squamous cell lung cancer: impact for drug discovery.
Singh AP; Adrianzen Herrera D; Zhang Y; Perez-Soler R; Cheng H
Expert Opin Drug Discov; 2018 Apr; 13(4):347-358. PubMed ID: 29394493
[TBL] [Abstract][Full Text] [Related]
7. Emerging challenges of advanced squamous cell lung cancer.
Zhang YC; Zhou Q; Wu YL
ESMO Open; 2016; 1(6):e000129. PubMed ID: 28255454
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
[TBL] [Abstract][Full Text] [Related]
10. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis G; Ziogas DC; Kyriazoglou A; Lykka M; Koutsoukos K; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):143. PubMed ID: 29862232
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Cell Oncol (Dordr); ; . PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
